ASCO GU

Company

Also known as: ASCO GU

Related News

Merck Presents Bladder and Kidney Cancer Data at 2026 ASCO GU Symposium

Mar 12, 2026

Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.

FDA Approves KEYTRUDA for Platinum-Resistant Ovarian Cancer

Feb 15, 2026

The FDA approved KEYTRUDA and its subcutaneous QLEX formulation for platinum-resistant ovarian cancer, marking the first PD-1 inhibitor cleared for this patient population based on Phase 3 results.